Iomeprol

CHEMBL2107214 Phase 4 Approuvé Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
777.1 g/mol
LogP
-2.3
Phase
4

This nonionic iodinated contrast agent is injected into blood vessels or body cavities to enhance visibility on CT scans and other X-ray procedures. It is considered safer than older ionic contrast agents because it causes fewer adverse reactions.

Masse moléculaire

777,1000 g/mol

LogP

-2,30

TPSA

180,00 Ų

Règle des 5 de Lipinski

Non conforme

Aires thérapeutiques

Mécanisme d'action

Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.

Structure 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CN(C(=O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I

InChI

InChI=1S/C17H22I3N3O8/c1-23(9(29)6-26)15-13(19)10(16(30)21-2-7(27)4-24)12(18)11(14(15)20)17(31)22-3-8(28)5-25/h7-8,24-28H,2-6H2,1H3,(H,21,30)(H,22,31)

Molecular Formula

C17H22I3N3O8

HBD / HBA

7 / 8

Liaisons Rotatives

10

Atomes Lourds

31

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

This nonionic iodinated contrast agent is injected into blood vessels or body cavities to enhance visibility on CT scans and other X-ray procedures. It is considered safer than older ionic contrast agents because it causes fewer adverse reactions.

Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.

Yes, Iomeprol is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2107214. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 3731. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.